Outcomes for complete versus noncomplete responders after 1 year of treatment with anti-interleukin-5 biologics

Complete respondersNoncomplete respondersΔ complete versus Δ noncomplete responders p-value
Clinical outcomes
 Exacerbations in previous 12 months, n0.008
  At baseline2.80±2.613.43±3.61
  At 12 months01.48±1.71
  At baseline53 (18)134 (63)
  At 12 months0123 (58)
Budesonide-equivalent dose, µg0.0006
  At baseline1600 (1200–1600)1600 (1600–2000)
  At 12 months1600 (800–1600)1600 (1600–2000)
 FEV1, L<0.0001
  At baseline2.26±0.852.18±0.83
  At 12 months2.47±0.872.21±0.85
  Δ from baseline0.210.03
 FEV1, % pred<0.0001
  At baseline70±2168±21
  At 12 months76±2070±22
  Δ from baseline62
  At baseline0.64±0.130.65±0.13
  At 12 months0.67±0.100.65±0.13
 FEV1 >80%0.008
  At baseline3131
  At 12 months4431
 ACQ score0.016
  At baseline2.32±1.322.67±1.24
  At 12 months1.28±1.111.99±1.26
  Δ from baseline−1.04−0.68
 ACQ ≤1.5<0.0001
  At baseline3321
  At 12 months6740
 Blood eosinophils, ×109 L−1<0.0001
  At baseline0.40 (0.18–0.65)0.23 (0.1–0.54)
  At 12 months0.06 (0.02–0.10)0.06 (0.02–0.10)
FENO, ppb0.71
  At baseline32 (18–64)32 (14–63)
  At 12 months29 (16–54)30 (16–60)

Data are presented as mean±sd, n (%), % or median (interquartile range), unless otherwise stated. mOCS: maintenance oral corticosteroids; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ: Asthma Control Questionnaire; FENO: exhaled nitric oxide fraction.